Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Mahmutovic Persson, H. Falk HåKansson (hanna@trulylabs.com / Truly Labs AB, M. Village,Lund), P. öNnervik (per-ola@trulylabs.com / Truly Labs AB, M. Village,Lund), J. Persson (janne@trulylabs.com / Truly Labs AB, M. Village,Lund), L. E. Olsson (lars.e_olsson@med.lu.se / Department of Translational Medicine, M. Radiation Physics, L. University, M. Sweden,Malmö), K. Von Wachenfeldt (karin@trulylabs.com / Truly Labs AB, M. Village,Lund). LSC - 2018 - In vivo models of Drug Induced ILD; tools to study and improve drug safety. 2976

Member's Comments

No comment yet.

Related content which might interest you: Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Can blood investigations be utilised to predict treatment response to omalizumab? Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Drug treatment in a German real-life COPD cohort (DACCORD) Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Regulatory perspective on the use of lung imaging in drug development Source: Eur Respir Monogr 2015; 70: 233-252 Year: 2015 Automated video analysis of movements in learning the inhaled administration of drugs by patients: A validation study Source: International Congress 2016 – Abstracts in medical education, the web and the internet Year: 2016 Workshop 1: Lung Clearance Index – demonstration of devices utilised by the core facility; best practices and different approaches to communication with pharmaceutical companies Source: International Congress 2016 – PD5 Establishing core facilities for measuring clinical trial outcomes  Year: 2016 Patient characteristics of new initiators of glycopyrronium bromide (GLY) – A multinational, multi-database real-world drug-utilization study Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Functional Respiratory Imaging as a sensitive biomarker to assess therapeutic interventions in lung diseases Source: International Congress 2015 – Functional and imaging techniques for assessing lung, airway and respiratory muscles Year: 2015 Use of the medical device NOWOX® to identify patterns of oxygen use in patients participating to the COPD management European trial (COMET) Source: International Congress 2015 – Tele-rehabilitation in chronic lung diseases Year: 2015 Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017 Randomized, controlled study of the impact of a mobile health tool on asthma SABA use, control and adherence Source: International Congress 2016 – Non-inflammatory assessment of airway disorders Year: 2016 ADEPT, airway disease endotyping for personalized treatment: Interim analysis of asthma patients Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Long-acting anti-muscarinic agents (LAMA) frequency of use and clinical features of patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Use of national disease registries in the conduct of long-term post-authorisation drug safety studies (LTSSs) Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Late Breaking Abstract - ND-L02-s0201 treatment leads to efficacy in preclinical IPF models Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Better Medicines for Children - European regulation, European research networks, Funding opportunities Source: Research Seminar 2006 - Preventing respiratory sequelae in children diagnosed with cystic fibrosis by newborn screening Year: 2006 Patients’ opinion for their inhalation device. An assessment of convenience and use Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013